PPARG and metabolic dysfunction-associated steatotic liver disease: These observations strongly suggest that moderate inhibition of PPARγ activity may reduce the risk for developing hepatic steatosis induced by diet, and PPARγ antagonists may be useful for the treatment and prevention of NAFLD.